Exenatide vs Mod GRF 1-29
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Side-by-Side Comparison
| Aspect | Exenatide | Mod GRF 1-29 |
|---|---|---|
| Dose Range | 5 mcg–10 mcg | 100 mcg–200 mcg |
| Frequency | 2x daily | 3x daily |
| Cycle Length | 8–24 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. |
| Typical Dosage | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. |
| Administration | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. |
| Side Effects | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. |
| Best For |
What They Have in Common
Exenatide, Mod GRF 1-29 are both commonly used for:
Key Differences
Unique to Mod GRF 1-29:
Which Has Stronger Evidence?
- Fat Loss: Exenatide has stronger research support.
| Goal | Exenatide | Mod GRF 1-29 |
|---|---|---|
| Fat Loss | high | medium |
Key Studies
Exenatide
- Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.
Annals of neurology, 2025
- The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.
Brain : a journal of neurology, 2023
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
The Journal of clinical endocrinology and metabolism, 2021
Ready to Learn More?
Looking for trusted sources?